Richard D. Nanula was appointed chief financial officer of Amgen Inc. (biotechnology) in August 2001 and served as executive vice president starting May 2001. He resigned in 2007 amid an SEC inquiry as to why company executives did not immediately disclose negative findings from drug trials. Nanula has also worked with Boeing and Miramax.

Property Value
dbo:abstract
  • Richard D. Nanula was appointed chief financial officer of Amgen Inc. (biotechnology) in August 2001 and served as executive vice president starting May 2001. He resigned in 2007 amid an SEC inquiry as to why company executives did not immediately disclose negative findings from drug trials. Nanula has also worked with Boeing and Miramax. (en)
dbo:nationality
dbo:wikiPageEditLink
dbo:wikiPageExternalLink
dbo:wikiPageExtracted
  • 2019-09-28 09:49:33Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 3534062 (xsd:integer)
dbo:wikiPageLength
  • 6179 (xsd:integer)
dbo:wikiPageModified
  • 2019-09-28 09:48:11Z (xsd:date)
dbo:wikiPageOutDegree
  • 30 (xsd:integer)
dbo:wikiPageRevisionID
  • 918369101 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Richard D. Nanula was appointed chief financial officer of Amgen Inc. (biotechnology) in August 2001 and served as executive vice president starting May 2001. He resigned in 2007 amid an SEC inquiry as to why company executives did not immediately disclose negative findings from drug trials. Nanula has also worked with Boeing and Miramax. (en)
rdfs:label
  • Richard Nanula (en)
owl:sameAs
foaf:gender
  • male (en)
foaf:isPrimaryTopicOf
is foaf:primaryTopic of